Business Wire

Spanish Government Approves National Reimbursement of ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor) in Combination With KALYDECO® (ivacaftor)

Share

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that the Spanish Government has approved terms for the national reimbursement of ORKAMBI ® (lumacaftor/ivacaftor) and SYMKEVI ® (tezacaftor/ivacaftor) in combination with KALYDECO ® (ivacaftor) for eligible patients in Spain living with cystic fibrosis (CF).

Under the terms announced today, children ages 6 to 11 years with CF who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene can be treated with ORKAMBI. Patients ages 12 years and older who either have two copies of the F508del mutation, or one copy of the F508del mutation and a copy of one of the other 14 mutations approved within the license in which the CFTR protein shows residual activity, can be treated with SYMKEVI in combination with KALYDECO.

Ludovic Fenaux, Senior Vice President, Vertex International, commented, “Today’s announcement means ORKAMBI and SYMKEVI can be prescribed from the first of November 2019 for the approximately 600 eligible cystic fibrosis patients living in Spain, to treat the underlying cause of their disease. We thank the Spanish Authorities for their collaboration and commitment to working with us in an innovative way to come to a solution for patients. We would also like to acknowledge the medical community for their important input during this process.”

Vertex’s CF medicines are reimbursed in 17 countries around the world including Austria, Australia, Denmark, Germany, the Republic of Ireland, Italy, the Netherlands, Sweden and the U.S.

About CF
Cystic Fibrosis (CF) is a rare, life-shortening genetic disease affecting approximately 75,000 people worldwide. CF is a progressive, multi-system disease that affects the lungs, liver, GI tract, sinuses, sweat glands, pancreas and reproductive tract. CF is caused by a defective and/or missing CFTR protein resulting from certain mutations in the CFTR gene. Children must inherit two defective CFTR genes — one from each parent — to have CF. While there are many different types of CFTR mutations that can cause the disease, the vast majority of all people with CF have at least one F508del mutation. These mutations, which can be determined by a genetic test or genotyping test, lead to CF by creating non-working and/or too few CFTR proteins at the cell surface. The defective function and/or absence of CFTR protein results in poor flow of salt and water into and out of the cells in a number of organs. In the lungs, this leads to the buildup of abnormally thick, sticky mucus that can cause chronic lung infections and progressive lung damage in many patients that eventually leads to death. The median age of death is in the early 30s.

About ORKAMBI® (lumacaftor/ivacaftor) and the F508del mutation
In people with two copies of the F508del mutation, the CFTR protein is not processed and trafficked normally within the cell, resulting in little-to-no CFTR protein at the cell surface. Patients with two copies of the F508del mutation are easily identified by a simple genetic test.

Lumacaftor/ivacaftor is a combination of lumacaftor, which is designed to increase the amount of mature protein at the cell surface by targeting the processing and trafficking defect of the F508del-CFTR protein, and ivacaftor, which is designed to enhance the function of the CFTR protein once it reaches the cell surface.

For complete product information, please see the Summary of Product Characteristics that can be found on www.ema.europa.eu.

About SYMKEVI® (tezacaftor/ivacaftor) in combination with KALYDECO® (ivacaftor)
Some mutations result in CFTR protein that is not processed or folded normally within the cell, and that generally does not reach the cell surface. Tezacaftor is designed to address the trafficking and processing defect of the CFTR protein to enable it to reach the cell surface and ivacaftor is designed to enhance the function of the CFTR protein once it reaches the cell surface.

For complete product information, please see the Summary of Product Characteristics that can be found on www.ema.europa.eu.

About Vertex
Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has three approved medicines that treat the underlying cause of cystic fibrosis (CF) — a rare, life-threatening genetic disease — and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational medicines in other serious diseases where it has deep insight into causal human biology, such as sickle cell disease, beta thalassemia, pain, alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy and APOL1-mediated kidney disease.

Founded in 1989 in Cambridge, Mass., Vertex's global headquarters is now located in Boston's Innovation District and its international headquarters is in London, UK. Additionally, the company has research and development sites and commercial offices in North America, Europe, Australia and Latin America. Vertex is consistently recognized as one of the industry's top places to work, including nine consecutive years on Science magazine's Top Employers list and top five on the 2019 Best Employers for Diversity list by Forbes.

Special Note Regarding Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including, without limitation, the statements in the second, third and fifth paragraphs of the press release. While Vertex believes the forward-looking statements contained in this press release are accurate, these forward-looking statements represent the company's beliefs only as of the date of this press release and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those expressed or implied by such forward-looking statements. Those risks and uncertainties include, among other things, that data from the company's development programs may not support registration or further development of its compounds due to safety, efficacy or other reasons, and other risks listed under Risk Factors in Vertex's annual report and subsequent quarterly reports filed with the Securities and Exchange Commission and available through the company's website at www.vrtx.com. Vertex disclaims any obligation to update the information contained in this press release as new information becomes available.

(VRTX-GEN)

Contact information

International Media: +44 20 3204 5275
MediaInfo@vrtx.com

U.S. Media: 617-341-6992
MediaInfo@vrtx.com

Investors: 617-961-7163
InvestorInfo@vrtx.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Philip Morris International Inc. Announces Agreement with KT&G to Accelerate the Achievement of a Smoke-Free Future29.1.2020 03:00:00 EETPress release

Philip Morris International Inc. (PMI) (NYSE:PM) today announces a global collaboration agreement with the leading tobacco and nicotine company in South Korea, KT&G, to commercialize KT&G’s smoke-free products outside of the country. “To achieve PMI’s vision of a smoke-free future we must grow the smoke-free category worldwide which requires multiple players providing a wide array of better choices for adult smokers. While IQOS continues to be the leading product in the smoke-free category, and we plan to broaden our portfolio by launching IQOS MESH in the coming months, we believe that increased collaboration will benefit adult smokers by providing greater choice and drive accelerated adoption of smoke-free products worldwide,” said André Calantzopoulos, PMI’s Chief Executive Officer. “Our objective is that all adult smokers who would otherwise continue to smoke switch as soon as possible to better alternatives and abandon cigarettes to the benefit of their health, public health and s

Australia’s Simply Energy Selects Hansen Technologies To Advance The Digital Enablement Of Their Business29.1.2020 02:00:00 EETPress release

Hansen Technologies is pleased to announce that it has signed a new agreement with longstanding customer Simply Energy, to augment the energy retailer’s existing Hansen HubCX platform with Sigma Catalog and Sigma CPQ. The Australian retail arm of the global ENGIE group, Simply Energy has more than 720,000 customer accounts in Victoria, South Australia, New South Wales, the Australian Capital Territory, Western Australia and Queensland. Under the terms of this agreement, Hansen Technologies will deploy Sigma Catalog and Sigma CPQ, which constitute part of Sigma Systems’ Create-Sell-Deliver Portfolio. The deal marks a significant progression for Hansen since acquiring Sigma last year and represents a strategic insertion of Sigma’s portfolio into the energy market, while facilitating a more digitalized business approach for Simply Energy. Shannon Hyde, Chief Executive Officer, Simply Energy, commented: “In recent years, we have seen changes in the economic and regulatory landscape in Aust

IFF to Release Fourth Quarter & Full Year 2019 Results February 1229.1.2020 00:15:00 EETPress release

Regulatory News: IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), a leading innovator of taste, scent, and nutrition, announced that it will release its fourth quarter and full year 2019 earnings results following the market close on Wednesday, February 12, 2020. The management team will host a live webcast on Thursday, February 13, 2020 at 10:00 a.m. ET to discuss results and outlook with the investor community. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), we’re using Uncommon Sense to create what the world needs. As a collective of unconventional thinkers and creators, we put science and artistry to work to create unique and unexpected scents, tastes, experiences and ingredients for the products our world craves. Learn more at iff.com, Twitter , Fa

Milliken & Company Finalizes Acquisition of Borchers28.1.2020 22:00:00 EETPress release

Milliken & Company (“Milliken”), a global diversified manufacturer with more than a century and a half of materials science expertise, has formally acquired Borchers Group Limited (“Borchers”), a global specialty chemicals company known for its innovative high-performance coating additives and specialty catalyst solutions from The Jordan Company, L.P. (“TJC”). The transaction officially closed on Tuesday, January 28, 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200128005647/en/ “When great teams come together, big things happen,” stated Halsey Cook, Milliken & Company president and CEO on closing the deal. “I’m excited to combine Borchers’ capabilities with Milliken’s long-term view and focus on innovation and sustainability.” “Borchers brings expertise, products and customer knowledge in the paint and coatings industry,” commented Russ Rudolph, senior vice president, Milliken’s Coating Additives Business. “Combined

Andersen Global Announces Collaboration with Lipa Meir & Co.28.1.2020 17:30:00 EETPress release

Andersen Global entered into a collaboration with Lipa Meir & Co., one of the most established and reputable law firms in Israel, adding dimension to the organization’s existing presence in the Middle East. Led by Office Managing Partner Alon Pomeranc, Lipa Meir & Co., founded in 1987, is comprised of more than 80 legal professionals that specialize in a variety of legal services including corporate law, M&A, litigation & dispute resolution, antitrust & competition, banking & finance, energy & infrastructure, capital markets & securities, project finance, cleantech & clean energy, healthcare & life sciences, high-tech & technology, and real estate. The firm has also been consistently recognized by global legal directories, including Chambers and Partners, Legal 500, IFLR1000 and WTR. “Lipa Meir & Co. is committed to and routinely delivers legal services of the highest caliber, and we constantly strive to expand our service offerings,” Alon said. “Our goal is to act as a one-stop shop f

Adecco, World’s Largest HR Staffing Firm, Selects beqom to Advance Pay Processes28.1.2020 17:05:00 EETPress release

beqom, a cloud-based compensation management software provider, today announced that The Adecco Group, the world's largest human resources provider and temporary staffing firm and a Fortune Global 500 company, has selected beqom’s solution to manage its salary review and bonus compensation processes, integrating directly with Adecco's existing HRIS landscape. “After surveying the market, we found that beqom was clearly the best solution to automate our total remuneration processes,” says Audrey Vissac, Director of Compensation and Benefits at The Adecco Group, France. “We are convinced that beqom will enable us to stay true to our vision that people should be inspired, motivated, and developed to embrace the future of work, starting with our own employees.” beqom initially will be deployed for 9,000 employees in France. With more than 5,200 branches in more than 60 countries and territories around the world, The Adecco Group offers a wide variety of services that include temporary staf

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom